The European IBS-C drug market is estimated to reach a CAGR of 9.38% during the forecast period, 2020-2028. The availability of limited treatments, different lifestyle disorders, and poor untapped market are the major drivers of the potential drug market in the region. The growth of the IBS-C drug market of the European region is studied further by segmenting the region into countries such as Poland, the UK, France, Russia, Germany, Italy, Belgium, and the rest of Europe. In the UK, 17% of the overall people, with a prevalence of 11% among men and 23% among women, are suffering from IBS.

EUROPE IBS-C DRUG MARKET FORECAST 2020-2028

Europe Ibs-c Drug Market by Drug Type (Overview (Lubiprostone, Linaclotide, Stimulant Laxatives, Osmotic Laxatives, Others (Psyllium)), Pipeline Drug Analysis: Plecanatide)  by Prescription Type (Prescribed Drugs, Over the Counter Drugs) by Geography

Request free sample

The European IBS-C drug market is estimated to reach a CAGR of 9.38% during the forecast period, 2020-2028. The availability of limited treatments, different lifestyle disorders, and poor untapped market are the major drivers of the potential drug market in the region.

The growth of the IBS-C drug market of the European region is studied further by segmenting the region into countries such as Poland, the UK, France, Russia, Germany, Italy, Belgium, and the rest of Europe. In the UK, 17% of the overall people, with a prevalence of 11% among men and 23% among women, are suffering from IBS. However, 33-90% of patients do not consult a physician, and some are not diagnosed in spite of meeting the IBS criteria. The market is poor and naïve and needs a lot of awareness. However, the market can be seen as a potential market for pharmaceutical companies due to the high prevalence of IBS. Though Germany is known as the leading pharmaceutical market in Europe, the sector is predicted to grow at a modest CAGR of 1.7% to reach an estimated $65 billion by 2020. IBS, which affected about seven million people in Germany, is often considered psychosomatic. The natural cause of the disease is unknown, and many therapeutic interventions are not giving satisfactory results.

In countries like France, around nine million people are affected by IBS. The publication of Rome IV Criteria in 2016 provides increased sensitivity and specificity for diagnosing IBS, which is expected to reduce overall prevalence to around 5%. In Italy, the overall number of adults with severe IBS range between 229,900 and 1,410,800. In 1988, a group of physicians defined criteria known as ‘Rome Criteria’ to diagnose IBS more accurately.

AstraZeneca, headquartered in Cambridge, UK, operates in America, Europe, Asia, and other regions of the world. The company is focused on the discovery, development, manufacturing, and marketing of prescription pharmaceuticals, and biological products in the therapeutic areas.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • MARKET DEFINITION
      • KEY DRIVERS
        • MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
        • IBS CAN BE A HERITABILITY ISSUE
        • AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
      • KEY RESTRAINTS
        • STRICT FDA REGULATIONS
        • UNAWARENESS AND IGNORANCE AMONG PEOPLE
    1. KEY ANALYTICS
      • KEY INVESTMENT INSIGHTS
      • PORTER’S FIVE FORCE ANALYSIS
        • BUYER POWER
        • SUPPLIER POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • REGULATORY FRAMEWORK
    2. MARKET BY PRESCRIPTION TYPE
      • PRESCRIBED
        • BRANDED
        • GENERIC
      • OVER THE COUNTER
    3. MARKET BY DRUG TYPE
      • LUBIPROSTONE
      • LINACLOTIDE
      • STIMULANT LAXATIVES
        • BISACODYL
        • SENNA
      • OSMOTIC LAXATIVES
        • LACTULOSE
        • POLYETHYLENE GLYCOL
      • OTHER DRUG TYPES
    4. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    1. COMPANY PROFILES
      • CATALENT PHARMACEUTICALS SOLUTIONS
      • ABBOTT LABORATORIES
      • NOVARTIS PHARMA AG
      • ASTELLAS PHARMACEUTICALS
      • ARDELYX, INC.
      • SYNTHETIC BIOLOGICS, INC.
      • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
      • BAMA-GEVE, SLU
      • FERRING BV
      • IRONWOOD PHARMACEUTICALS, INC.
      • SALIX PHARMACEUTICALS LTD
      • NORGINE B.V.
      • PROMETHEUS LABORATORIES INC.
      • ALBIREO PHARMA INC
      • YUHAN CORP
      • ASTRAZENECA PLC
      • THE MENARINI GROUP
      • ONO PHARMACEUTICAL CO., LTD.
      • ACTAVIS NORDIC A/S

     

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – IBS-C DRUG

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: EUROPE IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 4: EUROPE IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 5: EUROPE IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 6: EUROPE IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

    TABLE 8: EUROPE IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 9: EUROPE IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)

    TABLE 11: PRODUCT PROFILE (LINACLOTIDE)

    TABLE 12: EUROPE IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 13: EUROPE IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 14: PRODUCT PROFILE (BISACODYL)

    TABLE 15: PRODUCT PROFILE (SENNA)

    TABLE 16: EUROPE IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 17: EUROPE IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 18: PRODUCT PROFILE (LACTULOSE)

    TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)

    TABLE 20: PRODUCT PROFILE (PSYLLIUM)

    TABLE 21: EUROPE IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 22: EUROPE IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

     

    LIST OF FIGURES

    FIGURE 1: DRUGS PULLED OFF FROM THE MARKET

    FIGURE 2: KEY INVESTMENT INSIGHTS

    FIGURE 3: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 4: OPPORTUNITY MATRIX

    FIGURE 5: VENDOR LANDSCAPE

    FIGURE 6: EUROPE IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019

    FIGURE 7: EUROPE IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)

    FIGURE 8: EUROPE IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)

    FIGURE 9: EUROPE IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)

    FIGURE 10: EUROPE IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)

    FIGURE 11: EUROPE IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019

    FIGURE 12: EUROPE IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)

    FIGURE 13: EUROPE IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)

    FIGURE 14: EUROPE IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)

    FIGURE 15: EUROPE IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

    FIGURE 16: EUROPE IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)

    FIGURE 17: EUROPE IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)

    FIGURE 18: EUROPE IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

    FIGURE 19: EUROPE IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)

    FIGURE 20: EUROPE IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)

    FIGURE 21: EUROPE IBS-C DRUG MARKET, BY REGION, 2019 & 2028 (IN %)

    FIGURE 22: UNITED KINGDOM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 23: GERMANY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 24: FRANCE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 25: ITALY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 26: RUSSIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 27: BELGIUM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 28: POLAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 29: REST OF EUROPE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    1. MARKET BY PRESCRIPTION TYPE
      • PRESCRIBED
        • BRANDED
        • GENERIC
      • OVER THE COUNTER
    2. MARKET BY DRUG TYPE
      • LUBIPROSTONE
      • LINACLOTIDE
      • STIMULANT LAXATIVES
        • BISACODYL
        • SENNA
      • OSMOTIC LAXATIVES
        • LACTULOSE
        • POLYETHYLENE GLYCOL
        • OTHER DRUG TYPES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type